DNA Ginkgo Bioworks Holdings, Inc.
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell en…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 What Needs To Be True To Buy Twist Bioscience Stock Now? A $10,000 holding in Twist Bioscience (TWST) a year ago is worth about $66,600 today. The same sum in the S&P 500 would be worth about $11,700. The company sells made-to-order DNA to drug makers and research labs. Its sales grow fast, but it still loses money. The price now counts on that growth lasting and the losses ending. How much has to go right for that price to hold. | ||
 Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know In the latest trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $8.58, marking a -8.43% move from the previous day. | ||
 Ginkgo Bioworks (DNA) Surges 11.1%: Is This an Indication of Further Gains? Ginkgo Bioworks (DNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. | ||
 Ginkgo Bioworks Holdings, Inc. (DNA) Rises As Market Takes a Dip: Key Facts Ginkgo Bioworks Holdings, Inc. (DNA) concluded the recent trading session at $7.06, signifying a +1% move from its prior day's close. | ||
 The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It’s Not Tech) Anthropic is racing toward a public debut in September with a healthcare AI pitch that could ignite a sector most investors are not watching. Five biotech names are already moving, and one has climbed nearly 400% in the past year alone. | ||
 Ginkgo Bioworks Q2 Earnings Call Highlights Ginkgo Bioworks (NYSE:DNA) reported second-quarter 2026 revenue of $20 million, down 48% from the year-earlier period, as the company continued to shift its focus toward autonomous laboratory systems, contract research services and related software. Chief Executive Officer Jason Kelly said the comp | ||
 Ginkgo Bioworks Holdings, Inc. Q2 2026 Earnings Call Summary Moby summary of Ginkgo Bioworks Holdings, Inc.'s Q2 2026 earnings call | ||